REGN FY 2019 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6.6B-2.3% YoY

Gross Profit

$5.6B85.1% margin

Operating Income

$2.2B33.7% margin

Net Income

$2.1B32.3% margin

EPS (Diluted)

$18.46

Cash Flow

Operating Cash Flow

$2.4B

Free Cash Flow

$2.0B

Stock-Based Comp.

$464M

Balance Sheet

Total Assets

$14.8B

Total Liabilities

$3.7B

Stockholders' Equity

$11.1B

Cash & Equivalents

$1.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6.6B	$6.7B	-2.3%
Gross Profit	$5.6B	$6.1B	-8.9%
Operating Income	$2.2B	$2.5B	-12.8%
Net Income	$2.1B	$2.4B	-13.4%